AstraZeneca commits to being carbon negative by 2030

AstraZeneca has announced its ambition to have zero carbon emissions from its global operations by 2025 and to ensure its entire value chain is carbon negative by 2030, bringing forward decarbon

AI-powered study backs anticoagulants for heart failure pati...

A new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of whether they already have atrial fibrillation (AF).

UK biotech PhoreMost to work with Otsuka on gene therapy pro...

Building on an R&D tie-up with an Indian stem cell institution last year, UK biotech PhoreMost has begun a collaboration with Japan’s Otsuka working on several gene therapy projects.

WHO criticises lack of big pharma antibiotic R&D

Big pharma still continues to look upon antibiotic resistance as somebody else’s problem, the World Health Organization has warned, in a dismal update outlining the lack of private investme

Despite benefits, blockchain adoption is slow in life scienc...

Lilly targets quarterly deals worth up to $5bn to boost R&D

Eli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as it seeks to build its R&D pipeline, its chief financial officer has said.